An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.
To enhance the immunogenicity of the Influenza H5N1 vaccine, we developed an oil-in-water nanoemulsion (NE) adjuvant. NE displayed good temperature stability and maintained particle size. More importantly, it significantly enhanced IL-6 and MCP-1 production to recruit innate cells, including neutrophils, monocytes/macrophages and dendritic cells to the local environment. Furthermore, NE enhanced dendritic cell function to induce robust antigen-specific T and B cell immune responses. NE-adjuvanted H5N1 vaccine not only elicited significantly higher and long-lasting antibody responses, but also conferred enhanced protection against homologous clade 1 as well as heterologous clade 2 H5N1 virus challenge in young as well as in aged mice. The pre-existing immunity to seasonal influenza did not affect the immunogenicity of NE-adjuvanted H5N1 vaccine.
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: wcao@cdc.gov.
Weiping
W
Cao
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
William G
WG
Davis
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jin Hyang
JH
Kim
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Juan A
JA
De La Cruz
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Andrew
A
Taylor
School of Chemistry and Biochemistry, the Petit Institute for Bioengineering & Bioscience, Georgia Institute of Technology, Atlanta GA, USA.
Grant R
GR
Hendrickson
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Amrita
A
Kumar
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Priya
P
Ranjan
School of Chemistry and Biochemistry, the Petit Institute for Bioengineering & Bioscience, Georgia Institute of Technology, Atlanta GA, USA.
L Andrew
LA
Lyon
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jacqueline M
JM
Katz
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Shivaprakash
S
Gangappa
Immunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Suryaprakash
S
Sambhara
D000276:Adjuvants, Immunologic; D000818:Animals; D000914:Antibodies, Viral; D004655:Emulsions; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000517:prevention & control; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D004655:Emulsions; D007252:Influenza Vaccines
Adaptive immunity; Adjuvant; H5N1 vaccine; Influenza; Innate immunity; Oil-in-water nanoemulsion